Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

GenScript ProBio Forms Partnership to Expedite Novel Products for Bio Immunitas

publication date: Feb 8, 2023

GenScript ProBio, a Nanjing biologics CDMO, partnered with London’s Bio Immunitas to develop novel therapies using Bio Immunitas’ human Recombinant Protein Platform (hRPP). Specifically, GenScript ProBio will fast-track Bio Immunitas' manufacturing and production from bench to bedside, providing IND-enabling CMC services for preclinical development of two recombinant protein products. Bio Immunitas is developing a novel treatment that stabilizes the immune system, acting as an anti-viral, anti-inflammatory and immunomodulator with an anti-ageing capability that clears senescent cells. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital